Evolv Q2 Revenue Jumps 34%, Loss Narrows; Material Weaknesses and SEC Probe Linger
EVLV sits 24% above its 52-week low of $4.865.
Summary
Evolv Technologies reported Q2 2026 revenue of $43.8M, a 34% increase, and a net loss of $9.3M, a significant improvement from $40.5M a year ago. The company remains under SEC investigation and has not yet remediated material weaknesses in its financial controls.
Key Events · Earnings and Guidance · EVLV
-
Q2 Revenue Surges 34%
Total revenue reached $43.8M, driven by a 260% increase in product revenue and 23% growth in subscription revenue, reflecting strong demand and a shift to the purchase subscription model.
-
Net Loss Narrows Sharply
Net loss improved to $9.3M from $40.5M in Q2 2025, helped by revenue growth, operating leverage, and a $1.7M gain from the change in fair value of public warrant liability.
-
ARR and RPO Show Healthy Growth
Annual Recurring Revenue grew 20% YoY to $132.7M, and Remaining Performance Obligations increased 5% from year-end to $312.6M, indicating strong future revenue visibility.
-
Material Weaknesses Remain Unresolved
The company disclosed that material weaknesses in internal control over financial reporting, which led to prior restatements, have not yet been remediated. Remediation efforts are ongoing.
Analysis · EVLV · Technology
A strong Q2 saw revenue climb 34% year-over-year to $43.8M, while the net loss narrowed sharply to $9.3M. Adjusted EBITDA swung to a positive $4.4M, and ARR expanded 20% to $132.7M. Yet the quarter's operational gains are shadowed by unremediated material weaknesses in internal controls and an ongoing SEC investigation into marketing practices. The class action settlement has been funded, and derivative lawsuits were settled in principle with governance reforms. Although the earnings momentum is clear, the overhang from control deficiencies and regulatory risk tempers the positive surprise.
At the time of this filing, EVLV was trading at $6.05 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.87 to $8.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.